How good are clinical severity and outcome measures for psoriasis: Quantitative evaluation in a systematic review

Journal of Investigative Dermatology

Volumn 130, Issue 4, 2010, Pages 933-943

  Spuls, Phyllis I ^a,d   Lecluse, Lidian L A ^a   Poulsen, Marie Louise N F ^a   Bos, Jan D ^a   Stern, Robert S ^b   Nijsten, Tamar ^c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b HARVARD MEDICAL SCHOOL   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Dutch Cochrane Centre   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BODY SURFACE; CLINICAL FEATURE; DISEASE SEVERITY; HUMAN; PHYSICIAN; PRIORITY JOURNAL; PSORIASIS; REVIEW; SCORING SYSTEM; SELF EVALUATION; SYSTEMATIC REVIEW;

CLINICAL TRIALS AS TOPIC; HUMANS; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77949542398     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2009.391     Document Type: Review

References (56)

1. Ashcroft DM, Po ALW, Williams HC et al. (1999) Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 141:185-191
2. Berth-Jones J, Grotzinger K, Rainville C et al. (2006) A study examining inter-and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment. Br J Dermatol 155:707-713
3. Bigby M, Gadenne AS (1996) Understanding and evaluating clinical trials. J Am Acad Dermatol 34:555-590
4. Both H, Essink-Bot ML, Busschbach J et al. (2007) Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol 127:2726-2739
5. Buzney EA, Kimball AB (2008) A critical assessment of composite and coprimary endpoints: a complex problem. J Am Acad Dermatol 59:890-896
6. Carlin CS, Feldman SR, Krueger JG et al. (2004) A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 50: 859-866
7. Ellis CN (2007) Scoring severity of psoriasis. JEADV 21(Suppl 1):30-69
8. Feldman SR (2004) A quantitative definition of severe psoriasis for use in clinical trials. J Dermatolog Treat 15:27-29
9. Feldman SR, Clark AR, Venkat AP et al. (2005) The Self-Administered Psoriasis Area and Severity Index provides an objective measure of psoriasis severity. Br J Dermatol 152:382-383
10. Feldman SR, Fleischer AB Jr, Reboussin DM et al. (1996) The self-administered psoriasis area and severity index is valid and reliable. J Invest Dermatol 106:183-186
11. Feldman SR, Krueger GG (2005) Psoriasis assessment tools in clinical trials. Ann Rheum Dis 64:ii65-8
12. Fleischer AB Jr, Feldman SR, Dekle CL (1999) The SAPASI is valid and responsive to psoriasis disease severity changes in a multi-center clinical trial. J Dermatol 26:210-215
13. Fleischer AB Jr, Feldman SR, Rapp SR et al. (1996) Disease severity measures in a population of psoriasis patients: the symptoms of psoriasis correlate with self-administered psoriasis area severity index scores. J Invest Dermatol 107:26-29
14. Fleischer AB Jr, Rapp SR, Reboussin DM et al. (1994) Patient measurement of psoriasis disease severity with a structured instrument. J Invest Dermatol 102:967-969
15. Fredriksson T, Lassus A, Salde L (1983) Reproducibility of clinical trials of topical glucocorticosteroids. Int J Dermatol 22:536-539
16. Fredriksson T, Pettersson U (1978) Severe psoriasis-oral therapy with a new retinoid. Dermatologica 157:238-244
17. Fredriksson T, Pettersson U (1979) Oral treatment of pustulosis palmo-plantaris with a new retinoid, Ro 10-9359. Dermatologica 158:60-64
18. Gottlieb AB, Chaudhari U, Baker DG et al. (2003) The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison. J Drugs Dermatol 2:260-266
19. Harari M, Shani J, Hristakieva E et al. (2000) Clinical evaluation of a more rapid and sensitive Psoriasis Assessment Severity Score (PASS), and its comparison with the classic method of Psoriasis Area and Severity Index (PASI), before and after climatotherapy at the Dead-Sea. Int J Dermatol 39:913-918
20. Jacobson CC, Kimball AB (2004) Rethinking the psoriasis area and severity index: the impact of area should be increased. Br J Dermatol 151:381-387
21. Jemec GB, Wulf HC (1997) The applicability of clinical scoring systems: SCORAD and PASI in psoriasis and atopic dermatitis. Acta Derm Venereol 77:392-393
22. Kanthraj GR, Srinivas CR, Shenoi SD et al. (1997) Comparison of computer-aided design and rule of nines methods in the evaluation of the extent of body involvement in cutaneous lesions. Arch Dermatol 133:922-923
23. Katz KA (2005) Psoriasis Area and Severity Index 50 as an endpoint in psoriasis trials: an unconvincing proposal. J Am Acad Dermatol 53:547-551
24. Kirby B, Fortune DG, Bhushan M et al. (2000) The Salford Psoriasis Index: an holistic measure of psoriasis severity. Br J Dermatol 142:728-732
25. Kirby B, Richards HL, Woo P et al. (2001) Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol 45:72-76
26. Kreft S, Kreft M, Resman A et al. (2006) Computer-aided measurement of psoriatic lesion area in a multicenter clinical trial-Comparison to physician's estimations. J Dermatol Sci 44:21-27
27. Krueger G, Koo J, Lebwohl M et al. (2001) The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 137:280-284
28. Lahti A, Kopola H, Harila A et al. (1993) Assessment of skin erythema by eye, laser Doppler flowmeter, spectroradiometer, two-channel erythema meter and Minolta chroma meter. Arch Dermatol Res 285:278-282
29. Langley RG, Ellis CN (2004) Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician's global assessment. J Am Acad Dermatol 51:563-569
30. Long CC, Finlay AY, Averill RW (1992) The rule of hand: 4 hand areas=2 FTU=1g. Arch Dermatol 128:1129-1130
31. Louden BA, Pearce DJ, Lang W et al. (2004) A simplified psoriasis area severity index (SPASI) for rating psoriasis severity in clinic patients. Dermatol Online J 10:7
32. Marks R, Barton SP, Shuttleworth D et al. (1989) Assessment of disease progress in psoriasis. Arch Dermatol 125:235-240
33. Naldi L, Svensson A, Diepgen T et al. (2003) Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. J Invest Dermatol 120: 738-741
34. NICE (2006) New NICE guidance to help sufferers of poriasis and psoriatic arthritis. http://www.nice.org.uk/nicemedia/pdf/2006-034PsoriasisJointLaunch. pdf
35. Ormerod AD, Dwyer CM, Weller R et al. (1997) A comparison of subjective and objective measures of reduction of psoriasis with the use of ultrasound, reflectance colorimetry, computerized video image analysis, and nitric oxide production. J Am Acad Dermatol 37:51-57
36. Papp KA, Henninger E (2005) Safe psoriasis control: a new outcome measure for the composite assessment of the efficacy and safety of psoriasis treatment. J Cutan Med Surg 9:276-283
37. Ramsay B, Lawrence CM (1991) Measurement of involved surface area in patients with psoriasis. Br J Dermatol 124:565-570
38. Rapaport MJ (2005) PASI 75. J Am Acad Dermatol 52:183-184
39. Rapp SR, Feldman SR, Exum ML et al. (1999) Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41:401-407
40. Sampogna F, Sera F, Abeni D (2004) Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol 122:602-607
41. Sampogna F, Sera F, Mazzotti E et al. (2003) Performance of the self-administered Psoriasis Area and Severity Index in evaluating clinical and sociodemographic subgroups of patients with psoriasis. Arch Dermatol 139:353-358
42. Savolainen L, Kontinen J, Alatalo E et al. (1998) Comparison of actual psoriasis surface area and the psoriasis area and severity index by the human eye and machine vision methods in following the treatment of psoriasis. Acta Derm Venereol 78:466-467
43. Savolainen L, Kontinen J, Roning J et al. (1997) Application of machine vision to assess involved surface in patients with psoriasis. Br J Dermatol 137:395-400
44. Schmitt J, Ford DE (2007) Understanding the relationship between objective disease severity, psoriatic symptoms, illness-related stress, health-related quality of life and depressive symptoms in patients with psoriasis-a structural equations modeling approach. Gen Hosp Psychiatry 29:134-140
45. Schmitt J, Langan S, Williams HC (2007) What are the best outcome measurements for atopic eczema? A systematic review. J Allergy Clin Immunol 120:1389-1398
46. Schmitt J, Wozel G (2005) The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 210:194-199
47. Serup J, Agner T (1990) Colorimetric quantification of erythema-a comparison of two colorimeters (Lange Micro Color and Minolta Chroma Meter CR-200) with a clinical scoring scheme and laser-Doppler flowmetry. Clin Exp Dermatol 15:267-272
48. Szepietowski JC, Sikora M, Pacholek T et al. (2001) Clinical evaluation of the self-administered psoriasis area and severity index (SAPASI). Acta Dermatovenerologica Alpina, Panonica et Adriatica 10:79-83
49. Terwee CB, Bot SD, de Boer MR et al. (2007) Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 60:34-42
50. Thomas CL, Finlay AY (2007) The "handprint" approximates to 1% of the total body surface area whereas the "palm minus the fingers" does not. Br J Dermatol 157:1080-1081
51. Tiling-Grosse S, Rees J (1993) Assessment of area of involvement in skin disease: a study using schematic figure outlines. Br J Dermatol 128: 69-74
52. van de Kerkhof PC (1992) On the limitations of the psoriasis area and severity index (PASI). Br J Dermatol 126:205
53. Vardy DA, Guberman D, Lichtenstein DA et al. (1993) Assessment of severity score in patients with psoriasis. Br J Dermatol 129:349-350
54. Weisman S, Pollack CR, Gottschalk RW (2003) Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis. J Dermatolog Treat 14:158-165
55. -(2007) The dutch national evaluation of applications of drugs (LABAG). www.labag.nl/info.htm
56. Yune Y-M, Park SY, Oh HS et al. (2003) Objective assessment of involved surface area in patients with psoriasis. Skin Res Technol 9:339-342